Tamoxifen for retroperitoneal fibrosis.
Retroperitoneal fibrosis is characterised by diffuse inflammatory proliferation of fibroblasts and the deposition of collagen fibrils throughout the retroperitoneum, especially in perivascular sites. This results in blockage of the ureters and other tubular retroperitoneal structures such as the vasculature and lymphatic channels. Left untreated, it typically follows a progressive and fatal course. The condition responds favourably to tamoxifen and several case reports describe an improvement in renal function on this therapy. This case report describes a subjective and objective functional improvement of lymphoedema secondary to retroperitoneal fibrosis with the use of tamoxifen.
Chambers
J C
JC
Katharine House Hospice, East End, Adderbury, Oxon, OX17 3NL, UK. dr.ch@mbers.info
McGovern
K
K
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000601:surgery; D006801:Humans; D008209:Lymphedema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012185:Retroperitoneal Fibrosis / Q000188:drug therapy*; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen